REG-Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Oculis signed an asset purchase agreement to acquire worldwide development and commercial rights to its lead candidate Privosegtor and early-stage asset ACT-02 from Accure Therapeutics. Total consideration includes a $3.8 million upfront cash payment and the issuance of up to 2,050,000 Oculis ordinary shares, effectively terminating the legacy license agreement and associated royalty obligations to Accure.
Key figures
- Drug Name
- Privosegtor (ACT-01)
- Deal Value Usd
- 3800000
- Shares Offered
- 2050000
- Second asset
- ACT-02
- Upfront cash chf
- 3100000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.